预约演示
更新于：2026-06-23
Apecotrep
更新于：2026-06-23
概要
基本信息
药物类型 小分子化药 |
别名 [4-(6-aminopyridazin-3-yl)piperidin-1-yl][5-(4-fluorophenoxy)-4-methoxypyridin-2-yl]methanone、阿佩可普、BI 764198 + [2] |
靶点 |
作用方式 拮抗剂 |
作用机制 TRPC6拮抗剂(transient receptor potential cation channel subfamily C member 6 antagonists) |
在研适应症 |
非在研机构- |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (欧盟)、孤儿药 (日本)、儿科研究计划 (欧盟)、突破性疗法 (中国) |
登录后查看时间轴
关联
14
项与 Apecotrep 相关的临床试验NCT07355296
PODOMOUNT-Basket, a Phase II, Multicentre, Randomised, 2-arm Parallel-group, Double-blind, Placebo-controlled Basket Trial to Assess Safety, Tolerability, PK, and Efficacy of BI 764198 in Four Proteinuric Kidney Diseases
NCT07220083
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants
NCT07308652
The Effect of Multiple Doses of Itraconazole on the Single-dose Pharmacokinetics of BI 764198 Following Oral Administration in Healthy Male Trial Participants (an Open-label, Non-randomised, Two-period, Fixed-sequence Design Study)
100 项与 Apecotrep 相关的临床结果
登录后查看更多信息
100 项与 Apecotrep 相关的转化医学
登录后查看更多信息
100 项与 Apecotrep 相关的专利（医药）
登录后查看更多信息
5
项与 Apecotrep 相关的文献（医药）2026-02-01LANCET
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
Article
作者: Kretzler, Matthias ; Prasad, Srinivasa ; Cross, Nicholas ; Gesualdo, Loreto ; Licarião Rocha, Fabia T ; Retlich, Silke ; Trachtman, Howard ; Kaufeld, Jessica ; Ye, Zhiming ; Meijers, Björn ; Lobmeyer, Maximilian T ; Chen, Qinkai ; Soleymanlou, Nima ; Derebail, Vimal K ; Ng, Monica Suet Ying ; Ji, Bo ; Workeneh, Biruh
BACKGROUND:
In focal segmental glomerulosclerosis (FSGS), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) overactivity might cause podocyte loss and progressive kidney function decline. This exploratory study assessed the safety and efficacy of a novel once-daily oral selective TRPC6 inhibitor, BI 764198.
METHODS:
This multicentre phase 2, double-blind, placebo-controlled, randomised controlled trial assessed BI 764198 (20 mg, 40 mg, or 80 mg once daily) versus placebo over 12 weeks in participants aged 18-75 years with biopsy-confirmed primary FSGS (based on the absence of clinical evidence of secondary cause) or with a disease-causing TRPC6 variant. The study took place in 31 sites in ten countries, and random allocation was performed centrally in blocks in a 1:1:1:1 ratio and was stratified according to use of corticosteroids. Participants were receiving stable conservative and immunosuppressive therapy, with screening urine protein-creatinine ratio (UPCR) at 1·0 g/g or greater and estimated glomerular filtration rate at 30 mL/min per 1·73 m2 or greater. The primary endpoint was the proportion of participants with proteinuria response (≥25% UPCR reduction from baseline) at week 12. Other key outcomes were safety and tolerability. The study was registered with ClinicalTrials.gov on Jan 27, 2022 (NCT05213624) and is complete as of Jan 3, 2025.
FINDINGS:
From March 10, 2022, to Sept 3, 2024, 139 participants were screened and 67 were randomly assigned to receive placebo or BI 764198 at doses of 20 mg, 40 mg, or 80 mg (five participants were randomly assigned in error and were not treated). 62 participants received treatment, two of whom had missing baseline or post-baseline UPCR measurements and were not included in the full analysis set. Overall, 37 participants (60%) were male and 25 participants (40%) were female; the mean age was 40·7 years (SD 12·6); and the majority of the trial cohort were White (39 [63%] of 62). Proteinuria responses were observed in eight (44%) of 18, two (14%) of 14, and six (43%) of 14 participants receiving BI 764198 20 mg, 40 mg, and 80 mg, respectively (16 [35%] of 46 for all BI 764198 doses) versus one (7%) of 14 receiving placebo; corresponding odds ratios (ORs) versus placebo were OR 10·0 (95% CI 1·6-118·1), 1·5 (0·2-19·5), and 6·0 (0·9-73·6) for the three doses of BI 764198, and 4·9 (1·0-48·8) for all doses combined. BI 764198 was well tolerated with no meaningful differences in adverse event frequencies across treatment arms; treatment-emergent adverse events were reported by 44 (71%) of 62 participants, with similar frequencies of adverse events observed in the placebo group (ten [71%] of 14) and BI 764198 groups (34 [71%] of 48).
INTERPRETATION:
BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials over longer treatment durations, enabling meaningful subgroup analyses, are planned to evaluate the safety and efficacy of BI 764198 treatment in FSGS and other conditions affected by podocytopathy.
FUNDING:
Boehringer Ingelheim.
2025-05-04EXPERT OPINION ON INVESTIGATIONAL DRUGS
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment
Article
作者: Atef Halabi ; Silke Retlich ; Armin Schultz ; Friedeborg Seitz ; Nima Soleymanlou ; Hauke S. Wülfrath ; Katrien Lemmens ; Wansuk Choi ; Maximilian T. Lobmeyer
BACKGROUND:
BI 764198 could reduce podocyte injury in focal segmental glomerulosclerosis (FSGS).
RESEARCH DESIGN AND METHODS:
Four Phase 1 BI 764198 trials: single rising dose (SRD) and multiple rising dose (MRD)/drug-drug interaction trials in healthy volunteers; relative bioavailability (rBA) study (food and formulations effects on pharmacokinetics; PK); and kidney impairment (KI) PK study.
RESULTS:
SRD trial: 4/54 BI 764198-treated participants (7.4%) had ≥ 1 investigator-defined drug-related adverse event (DRAE): headache (n = 3; 5.6%); diarrhea (n = 1; 16.7%). BI 764198 PK was approximately linear. MRD trial: DRAEs occurred in 5/32 (15.6%) participants receiving BI 764198 and 1/8 (12.5%) receiving placebo. Once-daily BI 764198 80 mg (10 days) did not alter midazolam PK. All BI 764198 formulations tested had similar rBA; food did not affect PK. KI study: geometric mean ratios for area under the plasma concentration-time curve were 147.8% and 177.7% for participants with moderate and severe KI, respectively (vs. without). Limitations include typically small Phase 1 sample sizes and open-label design for the rBA and KI trials.
CONCLUSIONS:
BI 764198 was well tolerated and could be taken with/without food; evaluation in FSGS is ongoing.
CLINICAL TRIAL REGISTRATION:
The trials are registered at www.clinicaltrials.gov with codes NCT03854552; NCT04102462; NCT04656288; NCT04176536.
2025-05-04EXPERT OPINION ON INVESTIGATIONAL DRUGS
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men
Article
作者: Tachibana, Yoshifumi ; Retlich, Silke ; Soleymanlou, Nima ; Sarashina, Akiko ; Yonemura, Takuma
BACKGROUND:
BI 764198 is a selective, oral transient receptor potential cation channel, subfamily C, member 6 inhibitor under investigation for focal segmental glomerulosclerosis.
RESEARCH DESIGN AND METHODS:
Phase I study in 44 Japanese male volunteers. Single dose part: BI 764198 20 mg (n = 6) vs. placebo (n = 2); multiple dose part: BI 764198 40, 80, or 160 mg (n = 9 each) or placebo (n = 9) as a single dose then multiple daily dosing for 2 weeks. Primary endpoint: participants with drug-related adverse events (DRAEs); secondary endpoints: pharmacokinetic.
RESULTS:
DRAEs were reported in 20.5% (9/44) of participants (total BI 764198 21.2% [7/33]; placebo 18.2% [2/11]), mostly diarrhea (total BI 764198 15.2% [5/33]; placebo 18.2% [2/11]) and headache (BI 764198 80 mg 11.1% [1/9]; BI 764198 160 mg 33.3% [3/9]). BI 764198 exposure increased near dose proportionally to 80 mg and was slightly higher than anticipated with 160 mg. Pharmacokinetics were similar in Asians and non-Asians after accounting for body weight. Limitations include small sample size per dose and short trial duration.
CONCLUSIONS:
BI 764198 was well tolerated; exposure increased near dose proportionally to 80 mg, as previously observed in predominantly White volunteers.
CLINICAL TRIAL REGISTRATION:
This study was registered on Clinical Trials.gov, identifier NCT04665700.
100 项与 Apecotrep 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 局灶性节段性肾小球硬化症 | 临床3期 | 美国 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 中国 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 日本 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 阿根廷 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 澳大利亚 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 比利时 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 巴西 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 保加利亚 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 加拿大 | 2026-02-16 | |
| 局灶性节段性肾小球硬化症 | 临床3期 | 克罗地亚 | 2026-02-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 24 | (Cohort 1: Classical hADME) | 壓鬱衊構窪夢積網構夢(餘襯膚鑰範願壓積夢餘) = 窪淵醖襯製鏇鹹鏇簾齋 醖窪蓋窪艱遞窪願淵鬱 (齋壓夢繭鏇艱窪網憲構, 6.23) 更多 | - | 2026-06-03 | |
(Cohort 2: Microtracer hADME) | 壓鬱衊構窪夢積網構夢(餘襯膚鑰範願壓積夢餘) = 簾網衊築選鬱蓋淵壓齋 醖窪蓋窪艱遞窪願淵鬱 (齋壓夢繭鏇艱窪網憲構, 6.04) 更多 | ||||||
临床2期 | 62 | 壓蓋網網淵築憲壓憲觸(繭夢顧齋獵壓糧繭選獵) = 願憲築鏇衊觸齋積簾衊 鑰淵選艱簾願膚夢鹹壓 (醖衊鹹淵鹹網網鏇構觸 ) 更多 | 积极 | 2026-02-01 | |||
壓蓋網網淵築憲壓憲觸(繭夢顧齋獵壓糧繭選獵) = 餘鏇積繭鏇簾醖憲築壓 鑰淵選艱簾願膚夢鹹壓 (醖衊鹹淵鹹網網鏇構觸 ) 更多 | |||||||
临床2期 | 67 | (BI 764198 20 mg) | 窪夢顧夢廠觸膚淵艱膚 = 膚壓夢壓鏇獵鹽襯範齋 蓋襯壓製壓構憲淵鏇醖 (廠選鹽廠獵範衊鹽齋遞, 顧憲蓋網構鹹蓋糧淵餘 ~ 積襯範襯鹽憲觸壓鏇壓) 更多 | - | 2026-01-12 | ||
(BI 764198 40 mg) | 窪夢顧夢廠觸膚淵艱膚 = 廠築窪窪顧夢範衊積廠 蓋襯壓製壓構憲淵鏇醖 (廠選鹽廠獵範衊鹽齋遞, 繭醖膚糧構襯鹹築齋膚 ~ 餘鬱積夢積願遞衊鑰鑰) 更多 | ||||||
临床2期 | 60 | 壓夢壓窪繭積鏇淵願襯(構憲糧廠艱獵顧築窪醖) = 餘獵鏇網鏇壓齋製齋選 憲窪衊繭膚積衊糧窪衊 (獵憲餘膚獵積顧廠觸製 ) | 积极 | 2025-11-08 | |||
壓夢壓窪繭積鏇淵願襯(構憲糧廠艱獵顧築窪醖) = 膚遞餘簾遞築積觸觸積 憲窪衊繭膚積衊糧窪衊 (獵憲餘膚獵積顧廠觸製 ) | |||||||
临床1期 | TRPC6 | 44 | 鏇構鏇鬱鏇顧窪壓積築(築壓糧願選鬱膚鹹構繭) = 襯遞網鏇衊壓網鏇範蓋 憲鹽鏇淵鏇構積齋鏇鏇 (製衊淵選鹹淵願鬱壓憲 ) 更多 | - | 2025-05-04 | ||
Placebo | 鏇構鏇鬱鏇顧窪壓積築(築壓糧願選鬱膚鹹構繭) = 鹹醖廠蓋遞衊鹹顧選蓋 憲鹽鏇淵鏇構積齋鏇鏇 (製衊淵選鹹淵願鬱壓憲 ) 更多 | ||||||
临床1期 | 54 | 獵廠鹽簾憲繭觸鹽鏇鏇(選餘鏇淵廠遞鹽範夢廠) = 1 participant (16.7%) experienced diarrhea 窪淵窪遞憲製淵簾鹹壓 (築壓簾構襯憲積鹹觸願 ) 更多 | 积极 | 2025-05-04 | |||
Placebo | |||||||
临床2期 | - | 壓憲遞範願糧築鹽餘窪(壓艱簾範製構積鹹遞選): days = 3.41 (95% CI, 0.49 ~ 6.34) 更多 | 不佳 | 2023-04-06 | |||
Placebo | |||||||
临床2期 | 133 | (BI 764198 Treatment Group) | 鬱範鬱繭膚憲窪構憲遞 = 鑰憲衊網選遞襯範艱獵 餘糧壓鹹壓蓋廠鹹範簾 (齋窪淵艱範壓網餘鏇網, 衊鹹糧構淵鑰鹽衊襯鏇 ~ 蓋蓋鹽齋築鹹構顧鏇窪) 更多 | - | 2022-04-11 | ||
Placebo (Placebo) | 鬱範鬱繭膚憲窪構憲遞 = 積廠鬱網餘積獵選選艱 餘糧壓鹹壓蓋廠鹹範簾 (齋窪淵艱範壓網餘鏇網, 窪憲窪繭願蓋積衊觸淵 ~ 艱窪齋構觸範積繭襯積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用